+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Perrigo Co Plc (PRGO) - Financial and Strategic SWOT Analysis Review

Perrigo Co Plc (PRGO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Perrigo Co Plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures, and distributes over-the-counter products, generic, specialty pharmaceutical company, nutritional products, and infant formulas and foods. The company’s major products include analgesics, gastrointestinal, personal care and derma therapeutics, clobetasol spray, clindamycin foam, mupirocin ointment, Ketoconazole, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drugs, supermarket and mass merchandise chains and direct sales representatives. The company has operational presence in various geographical regions such as Australia, Israel and China. Perrigo is headquartered in Dublin, Ireland.

Perrigo Co Plc Key Recent Developments

  • May 07, 2025: Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations
  • Apr 23, 2025: Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025
  • Feb 27, 2025: Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations
  • Jan 06, 2025: Perrigo Expands Its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Perrigo Co Plc - Key Facts
  • Perrigo Co Plc - Key Employees
  • Perrigo Co Plc - Key Employee Biographies
  • Perrigo Co Plc - Major Products and Services
  • Perrigo Co Plc - History
  • Perrigo Co Plc - Company Statement
  • Perrigo Co Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Perrigo Co Plc - Business Description
  • Business Segment: Consumer Self-Care Americas
  • Overview
  • Performance
  • Business Segment: Consumer Self-Care International
  • Overview
  • Performance
  • Geographical Segment: All Other Countries
  • Target Markets
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • Perrigo Co Plc - Corporate Strategy
  • Perrigo Co Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Perrigo Co Plc - Strengths
  • Perrigo Co Plc - Weaknesses
  • Perrigo Co Plc - Opportunities
  • Perrigo Co Plc - Threats
  • Perrigo Co Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Perrigo Co Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 07, 2025: Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations
  • Apr 23, 2025: Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025
  • Feb 27, 2025: Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations
  • Jan 06, 2025: Perrigo Expands Its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer
  • Nov 06, 2024: Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
  • Oct 15, 2024: WNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women''s Health
  • Sep 04, 2024: Perrigo Names Charles Atkinson as Executive Vice President, General Counsel and Secretary
  • Aug 19, 2024: Perrigo Hires David Ball as Executive Vice President and Chief Brand and Digital Officer
  • Aug 02, 2024: Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations
  • Jul 31, 2024: Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Perrigo Co Plc, Key Facts
  • Perrigo Co Plc, Key Employees
  • Perrigo Co Plc, Key Employee Biographies
  • Perrigo Co Plc, Major Products and Services
  • Perrigo Co Plc, History
  • Perrigo Co Plc, Subsidiaries
  • Perrigo Co Plc, Key Competitors
  • Perrigo Co Plc, Ratios based on current share price
  • Perrigo Co Plc, Annual Ratios
  • Perrigo Co Plc, Interim Ratios
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Perrigo Co Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Perrigo Co Plc, Performance Chart (2020 - 2024)
  • Perrigo Co Plc, Ratio Charts
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Perrigo Co Plc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Taro Pharmaceutical Industries Ltd
  • Abbott Laboratories
  • Viatris Inc
  • Sandoz Inc
  • Pfizer Inc
  • The Procter & Gamble Co
  • Lupin Ltd
  • Koninklijke Philips NV
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • LNK International Inc
  • Aurobindo Pharma Ltd
  • Stada Arzneimittel AG
  • Reckitt Benckiser Group Plc
  • PL Developments Copiague LLC
  • Novartis International AG
  • Glenmark Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Inc
  • Bayer AG